{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Guo Y"],"funding":["National Key Research and Development Project"],"pagination":["e12744"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12697889"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(46)"],"pubmed_abstract":["Recent progress in synthetic biology has empowered engineered probiotics to sense tumor-specific physicochemical signals, thereby facilitating targeted in situ drug delivery. Here, an engineered probiotic consortium capable of integrating multiple tumor microenvironment (TME) signals and orchestrating multi-therapeutic payloads release through an orthogonal quorum-sensing system is designed. The probiotic consortium can respond to three characteristic TME parameters, pH, hypoxia, and high-lactate levels, in order to achieve controlled release of lactate depletion enzyme (LdhA) for metabolic environment improvement and the programmed death ligand 1 (PD-L1) nanobody for immune checkpoint inhibition. Using the humanized PD-1 mouse model bearing hPD-L1 MC38 tumor and the humanized peripheral b"],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["An Engineered Probiotic Consortium Based on Quorum-Sensing for Colorectal Cancer Immunotherapy."],"pmcid":["PMC12697889"],"funding_grant_id":["2024YFA0918500"],"pubmed_authors":["Wu J","Kang G","Gao M","Zhu Z","Guo Y","Zhang Y","Huang H","Gao X","Yuan H","Wang Z","Wang L","Yin J"],"additional_accession":[]},"is_claimable":false,"name":"An Engineered Probiotic Consortium Based on Quorum-Sensing for Colorectal Cancer Immunotherapy.","description":"Recent progress in synthetic biology has empowered engineered probiotics to sense tumor-specific physicochemical signals, thereby facilitating targeted in situ drug delivery. Here, an engineered probiotic consortium capable of integrating multiple tumor microenvironment (TME) signals and orchestrating multi-therapeutic payloads release through an orthogonal quorum-sensing system is designed. The probiotic consortium can respond to three characteristic TME parameters, pH, hypoxia, and high-lactate levels, in order to achieve controlled release of lactate depletion enzyme (LdhA) for metabolic environment improvement and the programmed death ligand 1 (PD-L1) nanobody for immune checkpoint inhibition. Using the humanized PD-1 mouse model bearing hPD-L1 MC38 tumor and the humanized peripheral b","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T01:19:00.949Z","creation":"2026-05-24T03:12:31.222Z"},"accession":"S-EPMC12697889","cross_references":{"pubmed":["40999885"],"doi":["10.1002/advs.202512744"]}}